Immuno-oncology and Tumor Microenvironment

52 Items

All Items

Tumor hypoxia: Classification, detection, and its critical role in cancer progression

Yan Zhao, Bing Zhong, Jing-Yi Cao, Qian Wang, Jie Liang, Ke Lu, Sheng-Ming Lu

1672–1690
The MHC-I-dependent neoantigen presentation pathway predicts response rate to PD-1/PD-L1 blockade

Yuchen Zhang, Chen Yang, Yanchao Xu, Xiang Jiang, Jiajun Shi, Binghua Li, Decai Yu

1314–1321
The mechanism of high mobility group box-1 protein and its bidirectional regulation in tumors

Zhongjia Tian, Lin Zhu, Yutong Xie, Huan Hu, Qunli Ren, Jianguo Liu, Qian Wang

477–485
The impact of MITF expression on tumor-infiltrating lymphocytes in melanoma: Insights into immune microenvironment dynamics

Damir Vučinić, Matea Lekić, Gordana Žauhar, Gordana Zamolo

2050–2057
The immunotherapy breakthroughs in cervical cancer: Focus on potential biomarkers and further therapy advances

Maja Pezer Naletilić, Krešimir Tomić, Kristina Katić, Zoran Gatalica, Gordan Srkalović, Eduard Vrdoljak, Semir Vranić

2594–2606
The assessment of tumor-infiltrating lymphocytes in invasive apocrine carcinoma of the breast in relation to the HER2 status

Zoran Gatalica, Nataliya Kuzmova, Inga Rose, Monika Ulamec, Melita Peric-Balja, Faruk Skenderi, Semir Vranic

256–261
Study on the mechanism of liver cancer immune escape mediated by MINDY1 through regulation of PD-L1 ubiquitination level

Xingchao Song, Wenjin Li, Chunyan Tian, Xiao Ma, Weibin Yang, Jiahua Zhou

144–154
Serum ferritin as a prognostic biomarker in CAR-T therapy for multiple myeloma: A meta-analysis

Jing Cheng, Yuan Song

2416–2427
Role of telomere maintenance genes as a predictive biomarker for colorectal cancer immunotherapy response and prognosis

Zhikai Wang, Chunyan Zhao, Yifen Huang, Chong Li

2696–2711
Role of gut microbiota and immune response in breast cancer progression

Xiaofang Zhang, Na Ma, Conghui Jin, Xiaoli Cao

100–114
Refining PD-1/PD-L1 assessment for biomarker-guided immunotherapy: A review

Marek Zdrenka, Adam Kowalewski, Navid Ahmadi, Rizwan Ullah Sadiqi, Łukasz Chmura, Jędrzej Borowczak, Mateusz Maniewski, Łukasz Szylberg

14–29
Progress of lymphocyte activation gene 3 and programmed cell death protein 1 antibodies for cancer treatment: A review

Yu-Quan Li, Xue-Mei Chen, Gui-Fei Si, Xue-Min Yuan

764-774
Prognostic value of immunotherapy in advanced NSCLC based on baseline and dynamic changes in HALP

Hui Su, Chao Yu, Guiming Sun, Baozhong Wang, Yingjie Gao, Xiaolan Liu, Qingcui Song, Xuezhen Ma

29–41
Prognostic significance and immunological role of HPRT1 in human cancers

Yiwen Lu, Ruixue Chen, Han Zhang, Xu Sun, Xiangjun Li, Mengyuan Yang, Xudong Zhang

262–291
Predictive value of TGF-β1 and SMAD-7 expression at diagnosis for treatment response in low-risk myelodysplastic syndrome

Bedrettin Orhan, Hülya Öztürk Nazlıoğlu, Oğuzhan Dik, Büşra Gürbüz, Vildan Özkocaman, Tuba Ersal, İbrahim Ethem Pınar, Cumali Yalçın, Sinem Çubukçu, Tuba Güllü Koca, Fazıl Çağrı Hunutlu, Şeyma Yavuz, Rıdvan Ali, Fahir Özkalemkaş

1175–1183
Prediction of pathologic complete response prediction in patients with locally advanced esophageal squamous cell carcinoma treated with neoadjuvant immunochemotherapy: A real-world study

Jifeng Feng, Liang Wang, Xun Yang, Qixun Chen, Xiangdong Cheng

153-160
Potent antitumor activity of a bispecific T-cell engager antibody targeting the intracellular antigen KRAS G12V

Changchang Lu, Lu Zou, Qiaoli Wang, Mengna Sun, Tianyu Shi, Shuang Xu, Fanyan Meng, Juan Du

1424–1434
Periplocin improves the sensitivity of oxaliplatin-resistant hepatocellular carcinoma cells by inhibiting M2 macrophage polarization

Jiefeng Weng, Hui Liu, Zhaofeng Wu, Yu Huang, Shuai Zhang, Yujie Xu

857–868
PD-L1 testing by immunohistochemistry in immuno-oncology

Semir Vranic, Zoran Gatalica

15-25
PD-L1 expression in testicular germ cell tumors undergoing spontaneous regression

Ivan Novak, Miroslav Tomić, Denis Mulabdić, Ivan Pezelj, Slaven Čiček, Igor Tomašković, Nino Sinčić, Božo Krušlin, Monika Ulamec

1751–1760

1-20 of 52 Next